Slowinska-Srzednicka J, Zgliczynski S, Jeske W, Stopinska-Gluszak U, Srzednicki M, Brzezinska A, Zgliczynski W, Sadowski Z
Department of Endocrinology, Medical Center for Postgraduate Education, Warsaw, Poland.
J Endocrinol Invest. 1992 Jul-Aug;15(7):533-8. doi: 10.1007/BF03348801.
In order to evaluate the effect of postmenopausal estrogen replacement therapy on the plasma levels of the insulin-like growth factor-I (IGF-I) 12 postmenopausal women aged 44 to 59 years were studied. The control group consisted of 15 healthy premenopausal women aged 20-44 years. In the postmenopausal women the plasma levels of IGF-I, gonadotrophins and sex hormones were determined before and after 3 and 6 months cyclic replacement therapy with transdermal 17 beta-estradiol (E2 100 micrograms patches applied twice weekly) combined with oral chlormadinone acetate (2 mg daily for 7 days in each cycle). Basal levels of estradiol (E2), IGF-I, dehydroepiandrosterone sulphate (DHEA-S), testosterone and androstenedione were lower, but gonadotropin levels were higher in postmenopausal than in premenopausal women. In all the women studied age was inversely correlated with IGF-I levels (r = -0.793, p less than 0.001) and with DHEA-S concentrations (r = -0.435, p less than 0.02). In postmenopausal women transdermal estradiol administration restored the circulating E2 levels to the early follicular range and increased the IGF-I levels (from 76.4 +/- 9.2 micrograms/l to 141.8 +/- 20.8 micrograms/l; p less than 0.01). Transdermal estradiol decreased gonadotrophin levels without changes in concentration of DHEA-S, testosterone, androstenedione and SHBG. In postmenopausal women before and during replacement therapy a positive correlation was found between estradiol and IGF-I concentrations (r = -0.439, p less than 0.01). These results suggest that cyclic replacement therapy with transdermal 17 beta-estradiol in combination with chlormadinone acetate given orally increase the plasma levels of IGF-I in postmenopausal women.
为了评估绝经后雌激素替代疗法对胰岛素样生长因子-I（IGF-I）血浆水平的影响，对12名年龄在44至59岁之间的绝经后妇女进行了研究。对照组由15名年龄在20 - 44岁之间的健康绝经前妇女组成。对于绝经后妇女，在采用经皮17β - 雌二醇（每周两次，每次使用100微克贴片）联合口服醋酸氯地孕酮（每个周期连续7天，每天2毫克）进行3个月和6个月的周期性替代治疗之前和之后，测定其IGF-I、促性腺激素和性激素的血浆水平。绝经后妇女的雌二醇（E2）、IGF-I、硫酸脱氢表雄酮（DHEA-S）、睾酮和雄烯二酮的基础水平较低，但促性腺激素水平高于绝经前妇女。在所有研究的女性中，年龄与IGF-I水平呈负相关（r = -0.793，p < 0.001），与DHEA-S浓度呈负相关（r = -0.435，p < 0.02）。在绝经后妇女中，经皮给予雌二醇可使循环E2水平恢复到卵泡早期范围，并提高IGF-I水平（从76.4±9.2微克/升升至141.8±20.8微克/升；p < 0.01）。经皮雌二醇降低了促性腺激素水平，而DHEA-S、睾酮、雄烯二酮和性激素结合球蛋白（SHBG）的浓度没有变化。在绝经后妇女替代治疗前和治疗期间，发现雌二醇与IGF-I浓度之间存在正相关（r = -0.439，p < 0.01）。这些结果表明，经皮17β - 雌二醇联合口服醋酸氯地孕酮的周期性替代治疗可提高绝经后妇女的IGF-I血浆水平。
